We truly enjoyed reading the recently published paper by Leiva et al. [
[1]
] who reported that the currently established CHA2DS2-VASC thrombotic risk score might
suboptimally perform in patients with myeloproliferative neoplasms (MPN) having atrial
fibrillation (AF). These findings are of high clinical importance and bring forward
awareness on unique cardiovascular risks of MPN patients.- Leiva O.
- Jenkins A.
- Rosovsky R.P.
- Leaf R.K.
- Goodarzi K.
- Hobbs G.
Predictors of increased risk of adverse cardiovascular outcomes among patients with
myeloproliferative neoplasms and atrial fibrillation.
J Cardiol. 2022; (S0914-5087(22)00269-6) (Online ahead of print. [Elsevier: Please update])https://doi.org/10.1016/j.jjcc.2022.10.007
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Predictors of increased risk of adverse cardiovascular outcomes among patients with myeloproliferative neoplasms and atrial fibrillation.J Cardiol. 2022; (S0914-5087(22)00269-6) (Online ahead of print. [Elsevier: Please update])https://doi.org/10.1016/j.jjcc.2022.10.007
- Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart survey on atrial fibrillation.Chest. 2010; 137: 263-272
- Advances in risk stratification and treatment of polycythemia vera and essential thrombocythemia.Curr Hemat Malig Rep. 2022; 17: 155-169
- No impact of the increased number of cardiovascular risk factors on thrombosis and survival in polycythemia vera.Oncol Res Treat. 2021; 44: 201-203
- Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis.Leuk Res. 2022; 119106905
Article info
Publication history
Published online: January 07, 2023
Accepted:
December 19,
2022
Received:
November 11,
2022
Publication stage
In Press Corrected ProofFootnotes
☆Conflict of interest: none.
☆Funding: none.
Identification
Copyright
© 2022 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
